New IV drug aims to tame gout flare pain in hours
NCT ID NCT07453004
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 2 trial tests punarlimab, a new IV drug, against a standard steroid injection for quick relief of acute gouty arthritis pain. About 170 adults with frequent gout flares will receive a single dose and report their pain levels over 72 hours. The goal is to see if punarlimab works better or as well as current treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- punarlimab (a drug given by IV)
- What this could lead to
- If it works, this could provide a new option for quickly easing severe gout pain during flare-ups.
- What could go wrong
- This is an early Phase 2 trial with only 170 people, so results may not apply to everyone. The drug may not work better than existing treatments or could have side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE GOUTY ARTHRITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Renji Hospital, Shanghai Jiao Tong University School of Medicine
RECRUITINGShanghai, Shanghai Municipality, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.